The recent surge in Kala-azar (Visceral Leishmaniasis) cases in Kenya serves as a stark reminder of the persistent global threat posed by this neglected tropical disease (NTD). For instance, an outbreak in Kenya’s arid regions saw cases rise dramatically from 1,575 in 2024 to 3,577 in 2025. This situation claimed a record number of lives due to missed diagnoses. Consequently, the disease, which sandflies spread, carries a 95 percent fatality rate if left untreated. Common symptoms include fever, substantial weight loss, and the enlargement of the spleen and liver. East Africa accounts for over two-thirds of global cases, according to the World Health Organization.
Kala-azar: The Global Risk and India’s Elimination Milestone
In contrast to the rising threat in East Africa, India has made significant strides towards eliminating Kala-azar as a public health problem. The country achieved the national elimination goal in 2023, defined as an incidence of less than one case per 10,000 population at the sub-district (block) level. This success is a result of intensified control programs and political commitment. However, physicians must remain vigilant. The parasitic disease is indigenous to 54 districts across four states—primarily Bihar, Jharkhand, West Bengal, and Uttar Pradesh. The Indian subcontinent is unique because Leishmania donovani is the only causative parasite, and Phlebotomus argentipes is the sole vector. Therefore, continued surveillance is critical to sustain the gains and prevent a resurgence, especially with factors like climate change expanding the sandfly’s range globally.
The situation in Kenya highlights several global challenges, including climate change effects that expand sandfly habitats. Furthermore, inadequate infrastructure means that remote areas like Mandera County have only a few facilities capable of treatment. This lack of access often leads to misdiagnosis, as was the case for one 60-year-old grandmother who was repeatedly treated for malaria and dengue fever for a year.
Treatment and Diagnosis Protocols for Kala-azar
Early diagnosis and prompt, complete treatment are essential for reducing the disease’s prevalence and fatality. The treatment regimen for Kala-azar is complex, often requiring daily injections and blood transfusions over a period of up to 30 days, which is costly in low-resource settings. For uncomplicated Kala-azar in India, the first-line treatment protocol is a single dose of injectable Liposomal Amphotericin B (L-AmB). Alternatively, oral Miltefosine (for 28 days) or a combination therapy may be used. Professionals seeking to deepen their understanding of managing complex infectious diseases might benefit from a Postgraduate Diploma In Infectious Disease.
Doctors must also monitor for special conditions, including relapse, Post-Kala-azar Dermal Leishmaniasis (PKDL), and HIV/VL co-infection. PKDL, a condition where Leishmania donovani invades skin cells, may appear years after treatment, creating a parasite reservoir and posing a threat to elimination efforts. Consequently, the management of these complex cases, as well as addressing malnutrition and weak immunity in affected populations, is vital to prevent future outbreaks. For physicians looking to enhance their dermatological skills, the Advanced Certificate Course In Dermatology offers relevant training.
Frequently Asked Questions
Q1: What are the key symptoms of Kala-azar (Visceral Leishmaniasis)?
A1: Kala-azar is characterized by irregular bouts of fever, significant weight loss, severe anemia, and the enlargement of the spleen and liver (hepatosplenomegaly).
Q2: What is the first-line treatment for Kala-azar in India?
A2: The first-line treatment for uncomplicated Kala-azar in India, as per national guidelines, is a single dose of injectable Liposomal Amphotericin B (L-AmB).
Q3: How does the Kala-azar threat in East Africa differ from India’s situation?
A3: India has neared elimination status, while East Africa continues to account for over two-thirds of the global cases, with recent surges driven by climate change and expanding human settlements. Moreover, East Africa faces challenges of limited treatment facilities and high rates of misdiagnosis, which escalate the fatality rate. Understanding how to manage cases in underserved or resource-limited environments is crucial for practitioners focusing on General Practice or global health initiatives.
References
- Neglected killer: Kala-azar surge in Kenya leaves record deaths, misseddiagnoses – ETHealthworld.
- The story of elimination of visceral leishmaniasis (kala-azar) in India—Challenges towards sustainment – PMC.
- Kala-azar elimination in India: Reflections on success and sustainability – PMC.
- Operational Guidelines on Kala-Azar (Visceral Leishmaniasis) Elimination in India – 2015 – mohfw.gov.in.
- Kala azar in India – Wikipedia.
- WHAT IS KALA-AZAR – National Center for Vector Borne Diseases Control (NCVBDC) – mohfw.gov.in.
Disclaimer: This article was automatically generated from publicly available sources and is provided for informational and educational purposes only. OC Academy does not exercise editorial control or claim authorship over this content. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider and refer to current local and national clinical guidelines.